Literature DB >> 10551374

Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.

F C Krebs1, S R Miller, D Malamud, M K Howett, B Wigdahl.   

Abstract

A highly desirable approach to prevention of human immunodeficiency virus type 1 (HIV-1) transmission during sexual intercourse is the development of nontoxic, topical, broad spectrum microbicides effective against transmission of cell-associated and cell-free virus. Toward this end, the HIV-1 inactivation potential of surface active agents C31G and an alkyl sulfate, sodium dodecyl sulfate (SDS) was assessed. Because of its extensive use as a microbicidal agent, nonoxynol-9 (N-9) was used as a reference against which C31G and SDS were compared. Viral inactivation was measured using HIV-1 LTR-beta-galactosidase indicator cells (expressing CD4 or CD4/CCR5) derived from HeLa cells, a cell line of human cervical adenocarcinoma origin. In experiments which examined inactivation of cell-free HIV-1, C31G was generally more effective than N-9. Viral inactivation by SDS occurred at twice the concentration necessary to achieve similar levels of inactivation using either N-9 or C31G. Using HeLa and HeLa-derived cells in cytotoxicity studies, it was demonstrated that SDS is as much as 11 and five times less cytotoxic than N-9 or C31G, respectively, during 48 h of continuous exposure. SDS (unlike C31G and N-9) can inactivate non-enveloped viruses such as human papillomavirus (HPV) [Howett, M.K., Neely, E.B., Christensen, N.D., Wigdahl, B., Krebs, F.C., Malamud, D., Patrick, S.D., Pickel, M.D., Welsh, P.A., Reed, C.A., Ward, M.G., Budgeon, L.R., Kreider, J.W., 1999. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob. Agents Chemother. 43(2), 314-321]. Since addition of SDS to C31G or N-9 may make the resulting microbicidal mixtures broadly effective against both enveloped and non-enveloped viruses, several surface active agent combinations were evaluated for their abilities to inactivate HIV-1. Addition of SDS to either C31G or N-9 resulted in mixtures that were only slightly less effective than equivalent concentrations of C31G or N-9 alone. To investigate inactivation of cell-associated infectivity, HIV-1 IIIB-infected SupT1 cells were treated with N-9, C31G, or SDS. Inactivation of cell-associated infectivity required higher microbicide concentrations than were needed for inactivation of cell-free virus. However, the relative activities of N-9, C31G, or SDS were similar to those seen in assays of inactivation using cell-free virus. These studies suggest that C31G and SDS may be attractive candidates for human trials as topical microbicides effective against HIV-1 transmission since both function at concentrations that provide effective viral inactivation with low levels of cytotoxicity. SDS microbicides (used alone or with other microbicides) may provide the added advantage of protection from HPV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551374     DOI: 10.1016/s0166-3542(99)00044-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  32 in total

1.  Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases.

Authors:  S Roy; P Gourde; J Piret; A Désormeaux; J Lamontagne; C Haineault; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial.

Authors:  Anne E Burke; Kurt Barnhart; Jeffrey T Jensen; Mitchell D Creinin; Terri L Walsh; Livia S Wan; Carolyn Westhoff; Michael Thomas; David Archer; Hongsheng Wu; James Liu; William Schlaff; Bruce R Carr; Diana Blithe
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

Review 3.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

4.  Comparative safety evaluation of the candidate vaginal microbicide C31G.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Elizabeth B Neely; Lynn R Budgeon; Mary L Ferguson; Catherine Stiller; Shendra R Miller; Daniel Malamud; Fred C Krebs; Mary K Howett; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Enhanced removal of a human norovirus surrogate from fresh vegetables and fruits by a combination of surfactants and sanitizers.

Authors:  Ashley Predmore; Jianrong Li
Journal:  Appl Environ Microbiol       Date:  2011-05-27       Impact factor: 4.792

6.  Antimicrobial evaluation of N-alkyl betaines and N-alkyl-N, N-dimethylamine oxides with variations in chain length.

Authors:  C R Birnie; D Malamud; R L Schnaare
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 7.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

8.  A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Robert F Rando; Mohamed Labib; Fred C Krebs
Journal:  J Biomed Biotechnol       Date:  2010-05-31

9.  The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model.

Authors:  James M Hill; Ethan M Stern; Partha S Bhattacharjee; Daniel Malamud; Christian Clement; Paulo Rodriguez; Walter J Lukiw; Augusto C Ochoa; Timothy P Foster; Cruz Velasco; Harris E McFerrin
Journal:  Antiviral Res       Date:  2013-07-13       Impact factor: 5.970

10.  Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.

Authors:  Hosahudya Gopi; M Umashankara; Vanessa Pirrone; Judith LaLonde; Navid Madani; Ferit Tuzer; Sabine Baxter; Isaac Zentner; Simon Cocklin; Navneet Jawanda; Shendra R Miller; Arne Schön; Jeffrey C Klein; Ernesto Freire; Fred C Krebs; Amos B Smith; Joseph Sodroski; Irwin Chaiken
Journal:  J Med Chem       Date:  2008-04-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.